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Drug formulationsAbstract A sensitive and speciﬁc luminescence method for the determination of Fexofenadine
(FEX), in pharmaceutical formulations is reported. The method is based on the sensitization of ter-
bium (Tb3+) by complex formation with FEX. The luminescence signal for Tb–FEX complex is
greatly enhanced by the addition of triethylamine (ET3N) and zinc nitrate in methanol solution.
Monitoring of the signal is accomplished when the instrument is in the phosphorescence mode with
the excitation and emission wavelengths set at kex = 220 nm and kem = 550 nm respectively.
Optimum conditions for the formation of the complex in methanol were 2.25 · 106 M of Tb3+,
5.00 · 106 M of Et3N and Zn2+ which allows for the determination of 10–800 ppb of FEX in
the batch mode with a detection limit of 0.3 ppb. The proposed method was successfully applied
for the determination of FEX in pharmaceutical formulations.
ª 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is
an open access article under theCCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Fexofenadine (FEX), (±)-4-[1-hydroxy-4-(4-hydroxydiphenyl
methyl)-1-piperidinyl]-butyl]-a,a-dimethyl benzene acetic acid
(Fig. 1), is a non-cardiotoxic second-generation histamine
H1-receptor antagonist in piperidine-class drugs used to treathay fever symptoms. It does not cause sedation or other cen-
tral nervous system effects because it does not cross the
blood–brain barrier (Simpson and Jarvis, 2000).
Fexofenadine does not have a negative effect on the psy-
chomotor efﬁciency. The substance has anti-inﬂammatory
characteristics, which presents a modern approach to allergy
therapy. Besides, fexofenadine may prove a safer alternative
in the treatment of asthma and atopic dermatitis (Meeves
and Appajosyula, 2003; Kawashima and Hirodi, 2007) and is
rapidly absorbed with a long duration of action, making it
suitable for once daily administration.
Several analytical methods have been reported for the
analysis of FEX in biological ﬂuids and pharmaceutical
formulations. These methods include high performance liquidulations.
Figure 1 Chemical structure of fexofenadine.
2 S.M.Z. Al-Kindy et al.chromatography (HPLC) (Uno et al., 2004; Pankaniya et al.,
2013; Krakus et al., 2008), capillary electrophoresis (Breier
et al., 2005; Mikus et al., 2005), mass spectrometric methods
(Guo et al., 2010; Hofmann et al., 2002), spectrophotometric
methods (Gazy et al., 2002; Naravana and Veena, 2010;
Ashour et al., 2013), and chemiluminescence (CL) method
(Al-Lawati et al., 2011).
Recently, the use of spectroﬂuorimetric techniques for the
quantiﬁcation of FEX was reported. The determinations were
carried out using indirect methods such as ﬂuorescence
quenching (Alothman et al., 2010) and derivatization tech-
niques (Eid and Wahba, 2012; Ibrahim et al., 2011). The native
ﬂuorescence of FEX occurs in the ultraviolet region, which
may be subjected to interference with the matrix. However,
the drug contains a carboxylic acid group, which is known
to form complexes with many metals such as Tb3+ and
Eu3+. The complexes absorb energy at the characteristic wave-
length of the ligand and emit radiation at the characteristic
wavelength of the lanthanide ions (Ln (III). Lanthanide ions
are characterized by low luminescence quantum yields due to
their weak molar absorptivity. However, the quantum yields
are tremendously enhanced by chelating the lanthanides with
suitable organic ligands that have broad intense absorption
bands. The excited state of the ligand, transfers energy
intramolecularly to the emitting level of the Ln (III) ion and
thus serves as an antenna chromophore.
As part of our continuous efforts on developing methods
on drug analysis (Al-Kindy and Suliman, 2007; Al-Kindy
et al., 2007, 2004, 2012, 2008), we report a novel luminescence
method based on the enhancement and sensitization of ter-
bium brought about by complexation with FEX.
Determination of FEX after complexation with europium
was recently reported (AbdEl-Hay et al., 2012). However,
the signal was monitored by ﬂuorescence technique, which
was accompanied by scattering due to second order emission.
Herein we report an improved method based on sensitized time
resolved luminescence of terbium in the presence of Zn2+ and
Et3N. To our knowledge, this is the ﬁrst time that the effect of
Zn2+ and Et3N on co-luminescence agent is investigated in a
carboxylic acid system. The luminescence properties were
investigated in various solvents. Factors affecting complexa-
tion such as the concentration of Tb3+ and the ratio of
Tb3+ to FEX as well as the effect of co-ligands and co-
luminescence agents on the luminescence properties of FEX–
Tb3+ have been carefully studied. The method was subse-
quently used to determine the concentration of FEX in phar-
maceutical samples. Our experimental results were validated
by a ﬂuorimetric method.Please cite this article in press as: Al-Kindy, S.M.Z. et al., Terbium sensitized lumin
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2.1. Apparatus
Luminescence measurements were performed using Perkin
Elmer LS-55 luminescence spectrometer (Perkin Elmer,
Beaconsﬁeld UK) equipped with a xenon discharge ﬂash lamp.
The operation and data processing were controlled by the ﬂuo-
rescence Data Manager Software. The excitation and emission
wavelengths were set at 220 nm and 550 nm respectively. The
instrument was operated in a phosphorescence mode with a
gate time of 0.04 ms and a delay time of 0.2 ms used through-
out the measurements. Absorption spectra were recorded on a
Varian CARY 50 Conc UV visible spectrophotometer
(Connecticut, USA) with 1 cm matched quarts cell.
2.2. Reagents
HPLC grade methanol, ethanol, 1-propanol, acetone and ace-
tonitrile were purchased from Sigma–Aldrich (St Louis, Mo,
USA). Terbium (III) chloride hexahydrate and triethylamine
were purchased from Kanto Chemical CO. INC (Tokyo,
Japan). Zinc nitrate was obtained from (BDH Chemicals Ltd
pool England). FEX standard was obtained from the Quality
Control Laboratory, Ministry of Health, Muscat, Sultanate
of Oman.
Pharmaceutical formulations: Telfadin 180 mg (Muscat,
Sultanate of Oman), Telfast 120 mg (France) and Fexodine
120 mg (Tabuk, Saudi Arabia) were purchased from local
retail outlets.
2.3. Preparation of standard solutions
1.14 · 103 M of FEX stock standard solution was prepared in
methanol. Working standard solutions were freshly prepared
by appropriate dilutions of the stock with methanol.
Terbium (III) chloride hexahydrate stock solution
(1.31 · 103 M) was prepared by dissolving 24.5 mg of Tb3+
in 50 mL methanol. Working standard solutions were freshly
prepared by appropriate dilution of the stock solution with
methanol. 2.00 · 103 M stock solution of triethylamine was
prepared by dissolving 0.01 g of the reagent in 50 ml methanol.
Stock solutions (2.00 · 103 M) of various co-luminescent
agents such as zinc nitrate, gadolinium, samarium, lanthanum,
and europium were prepared in methanol.
2.4. Preparation of drug samples
Three commercial products containing known amounts of
FEX were analyzed. Five tablets of each product were sepa-
rately weighed, and then the tablets were powdered and mixed.
A portion of the powder known to contain an equivalent
amount of one tablet was accurately weighed and
sonicated with methanol for 30 min. It was then ﬁltered into
a volumetric ﬂask and completed to the mark with methanol
to make a stock solution. Working solutions of 50 ppm in
methanol were prepared. Appropriate aliquots from the work-
ing solution were taken for the determination of FEX in
samples.escence for the determination of fexofenadine in pharmaceutical formulations.
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3.1. Spectral characteristics
The absorption spectrum of FEX and Tb–FEX complex in
methanol was found to exhibit two bands in the ultraviolet
region at 202 nm and 219 nm. A slight enhancement in the
absorption was observed in the presence of the complex when
compared to the ligand alone.
On the other hand, the ﬂuorescence spectrum of
1.0 · 105 M of FEX in methanol revealed a notable ﬂuores-
cence signal in the low UV region with an emission wavelength
at 298 nm when excited at 252 nm. The emission characteristic
at low UV region will not be analytically useful particularly for
the analysis of the drug in biological solution. This is due to
the possible interference of short-life emitting species from
the matrix.
In order to improve the analytical characteristics for the
determination of FEX in pharmaceutical formulation, the sys-
tem of (Tb–FEX) in methanol was investigated. FEX was used
to sensitize the luminescence of terbium ion. Terbium exhibited
a weak luminescence in methanol. However, when FEX was
added to the Tb3+ solution, the intensity of Tb3+ peaks was
enhanced about six times compared to that of Tb3+ alone as
shown in Fig. 2. The signal of Tb–FEX resulted in the well-
structured emission bands of Tb3+ while the excitation spectra
of Tb3+ revealed the presence of a band at 216 nm. Upon
addition of FEX to Tb3+ solution, a broad band slightly red
shifted to 220 nm was observed (ﬁgure not shown).
The enhancement of the luminescence of Tb3+ ions upon
addition of FEX is probably due to complexation of the ions
by the drug with the ensuing efﬁcient transfer of energy from
FEX to the chelated Tb3+, which can overcome the low extinc-
tion coefﬁcient of the ions. For efﬁcient energy transfer to
occur, the sensitizing moiety must absorb light in the ultravio-
let region, which is the case for FEX. The close agreement
between the absorption spectra of the ligand at 219 nm and
the excitation spectra at 220 nm support that the excitation
of the antenna may be the only photophysical pathway leadingFigure 2 Luminescence emission spectra of: (1) Tb3+ in MeOH
system, (2) Tb3+ in presence FEX in MeOH. [Tb3+] = 2.3 ·
106 M, [FEX] = 1.0 · 106 M, kex = 220 nm, kem = 550 nm.
Please cite this article in press as: Al-Kindy, S.M.Z. et al., Terbium sensitized lumin
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Furthermore, a complete overlap between the absorption spec-
trum of FEX and the excitation spectrum of Tb–FEX complex
is observed. The emission spectrum of Tb–FEX complex when
excited by the p–p* absorption band of the complex at 220 nm
revealed the well-known bands of terbium luminescence.
Among these transitions, the 5D4–
7F5 around 545 nm is the
strongest followed by the one at 490 nm. Therefore, the peak
height at 550 nm was used to measure the luminescence inten-
sity of the Tb–FEX complex. Moreover a large stokes shift of
330 nm was observed, indicating that there is no overlap
between the Tb3+ emission band and the antenna chro-
mophore absorption bands.
The luminescence intensity of Tb3+ at 550 nm is affected by
the coordination environment. Hence the effect of solvent,
concentration of Tb3+ and FEX, Et3N and Zn
2+ and effect
of different co-luminescence reagents were investigated in
order to maximize the luminescence intensity.
3.2. Effect of solvent
The inﬂuence of the solvents on the luminescence intensity of
FEX–Tb3+ complex was investigated carefully and the
results are shown in Fig. 3. It can be seen that the enhancing
effect of organic solvents in the Tb–FEX system is arranged
in the order CH3OH > CH3CN > C2H5OH > C3H7OH >
(CH3)2CO > H2O. The dielectric constants (e) of these sol-
vents are methanol 32.6, acetonitrile 37.5, ethanol 24.5, propa-
nol 20.3, acetone 20.4 and water 78.8. It is clear that there is an
agreement between dielectric constant (e) of the solvents that
contain oxygen atoms and the luminescence in the system
apart from methanol and water. It has been reported, that
the difference in intensity of the emission line between the four
alcoholic solutions indicates the different coordination behav-
ior of alcohols with terbium metal with methanol exhibiting
the strongest coordination ability (AbdEl-Hay et al., 2012).
Similar results were previously reported for terbium and euro-
pium complexes, where maximum sensitization was observed
in the presence of methanol (Al-Kindy et al., 2008; DangFigure 3 Effect of type of solvent on terbium sensitized
luminescence emission spectra. [FEX] = 1.03 · 105 M, [Tb3+]
= 2.89 · 105 M, kex = 220 nm, kem = 550 nm (1) methanol, (2)
acetonitrile, (3) ethanol, (4) propanol, (5) acetone, and (6) water.
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Figure 5 Continuous variation method of the Tb (FEX) complex
in MeOH. [Tb3+] = [FEX] = 2.0 · 105 M, kem = 550 nm,
kex = 220 nm.
4 S.M.Z. Al-Kindy et al.et al., 2007; Qin et al., 2003). The emission intensity decreases
with increase in the alkyl chain in alcohols (Ansari et al., 2007).
The low sensitization in water may be due to the O–H oscilla-
tors of water molecules that are known to quench the excited
state of the lanthanide ions by interaction with high-energy
vibrations associated with O–H. Solvent molecules can usually
replace coordinated water and avoid high frequency O–H
bond vibration––thus greatly decreasing energy loss resulting
through the coordination of water molecules, and increasing
the ﬂuorescence intensity of the emitting lanthanide ion. This
suggests that the chemical environment plays an important
role in determining the ﬂuorescence intensity of the complexes;
hence, the choice of methanol was ideal in studying the
luminescence of the Tb–FEX complex.
3.3. Stoichiometry of the Tb–FEX complex
Since the sensitization results from complex formation
between FEX and Tb3+, it is necessary to optimize the ratio
of the concentration of the metal to the ligand that will result
in maximum complexation and hence maximum intensity of
the emission line of terbium ion. The optimum concentration
of terbium was determined by measuring the luminescence
intensity of various molar ratios of Tb3+:FEX. The lumines-
cence intensity increased with an increased concentration of
FEX and reached a maximum value at a ratio of 1:3 after
which the intensity remained constant (Fig. 4) indicating the
formation of Tb (FEX)3 complex.
The stoichiometry of the complex was corroborated using
Job’s plot of continuous variation. Equal concentration of
Tb3+ and FEX (2.0 · 105 M) was used, and the molar ratio
of Tb3+:FEX was varied. The luminescence intensity increased
with an increase in the mole fraction of Tb3+:FEX and
reached a maximum at a mole fraction of 0.3 (Fig. 5), indicat-
ing a stoichiometry of Tb3+:FEX of 1:3.
3.4. Luminescence enhancement of Tb–FEX complex by zinc and
Et3N
One of the strategies to improve the luminescence of lan-
thanide system is the addition of co-luminescence agent.
Non-ﬂuorescing lanthanide ions such as La3+, Gd3+ andFigure 4 Inﬂuence of [FEX]: [Tb3+] ratio on terbium
sensitized luminescence. [Tb3+] = 1 · 105 M, kex = 220 nm.
kem = 550 nm.
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cence of Tb3+ and Eu3+ complexes is enhanced (Yang et al.,
1994). In this case, the intermolecular energy ﬂow is believed
to occur between the non-ﬂuorescing donor complexes of
Ln3+, Gd3+ and Sm3+ to the ﬂuorescing acceptor complexes
of Tb3+, Eu3+ or Dy3+.
Initially the effect of addition of co-luminescence agents
such as Eu3+, La3+, Gd3+, Sm3+ and Zn2+ with the concen-
tration of 5.00 · 106 M was investigated. Addition of Zn2+
gave the highest luminescence intensity in this system.
However, other co-luminescence quenched the ﬂuorescence
of Tb3+ as shown in Fig. 6.
Most of the work on co-luminescence effect was reported in
aqueous system in the presence of micelles and synergistic
agents such as TOPO or 1, 10 phenanthroline. Recently,
(Dang et al., 2007) a new co-luminescence system was reported
in methanol, the system used b-diketonate as ligand. The sys-
tem of Tb-N-(2-pyridinyl) ketoacetamide was greatly enhanced
in the presence of zinc nitrate and triethylamine (Et3N).
In this study, the luminescence properties of Tb–FEX com-
plex were enhanced in the presence of Zn2+ and Et3N (Fig. 7).
It is clear from the ﬁgure that Tb3+ exhibited a weak signal inFigure 6 The effect of co-luminescence agents on the lumines-
cence spectra of Tb3+–FEX system. [Tb3+] = 2.25 · 106 M,
[FEX] = 7.5 · 107 M, [co-luminescence] = 5.00 · 106 M.
escence for the determination of fexofenadine in pharmaceutical formulations.
Figure 7 The emission spectra of Tb–FEX–Et3N–Zn (1), Tb–
FEX–Et3N, (2), Tb–FEX, (3) Tb
3+ alone, (4) system in methanol.
[Tb3+] = 2.25 · 106 M, [FEX] = 7.50 · 107 M, [Et3N] =
5.00 · 106 M and [Zn2+] = 5.00 · 106 M.
Terbium sensitized luminescence for the determination of fexofenadine 5methanol. When adding Et3N and FEX an enhancement of the
terbium ion signal is observed. However, a huge enhancement
in the signal is observed when Zn2+ was added to Tb3+ in the
presence of FEX and Et3N.
Many multinuclear heterometallic 3d–4f complexes were
reported (Towatari et al., 2013; Lu¨ et al., 2010; Yang et al.,
2005; Bi et al., 2009). The formation of these complexes was
evidenced by characterization by X-ray crystallography which
revealed the existence of functional bridge in these 3d–4f com-
plexes. The donation of OH groups was the main facilitator of
the formation of such complexes. In the coordination com-
pounds involving Zn2+ and lanthanide ions, it was reported
that complexation of a pyridine group to Zn2+ ions in these
complexes resulted in congestion around the coordination
sphere of the 4f Ln3+ ions (Bi et al., 2009). This has led to a
signiﬁcant minimization of the luminescence quenching from
solvents molecules around the lanthanide ions. On the other
hand, the involvement of heavy atoms in the structure
improves the antenna energy transfer signiﬁcantly. We believe
that a similar mechanism might be responsible for the enhance-
ment of the luminescence of Tb3+–ZN Et3N.
However, further work needs to be done to explain the
actual mechanism of the energy transfer, including synthesiz-
ing the complex in a large scale and verify it is structured by
X-ray crystallography.Table 1 Comparison with other methods for the determination of
Method Linear range (lg mL1)
HPLC with UV detection 24–120
HPLC with UV detection 5–40
CE (UV detection) 20–100
HPLC with Fluorescence 0.001–0.5
HPLC with Fluorescence 0.005–0. 8
Spectroﬂuorimetry 0.05–12.5
Spectroﬂuorimetry 0.2–3.5
LC–MS/MS 0.001–0.6
MF–CL 0.05–5.0
This work 0.01–0.8
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rescence intensity was studied. The maximum intensity of
luminescence was at the concentration of Et3N equal to
5.0 · 106 M. Therefore, 5.0 · 106 M was employed as the
ﬁnal Et3N concentration.
After optimizing the concentration of Et3N, the effect of
concentration of Zn2+ on the system was investigated. The
luminescence intensity increased with an increase in the con-
centration of zinc and maximum intensity was observed at a
concentration 5.0 · 106 M of zinc. On increasing the concen-
tration of zinc further, a decrease in the luminescence intensity
was observed. This could be due to the fact that a large excess
of Zn ions could result in favoring the formation of mononu-
clear Zn-complexes at the expense of the heteronuclear metal-
lic complexes. Hence, a 5.0 · 106 M of Zn2+solution was
used for the subsequent work.
3.5. Effect of Tb3+ concentration
The effect of Tb3+ concentration on the luminescence intensity
of the system was examined after optimizing all the other
parameters. The luminescence intensity starts to increase with
an increase in the concentration of Tb3+ until it reaches the
maximum at 2.25 · 106 M after which a decrease in the
luminescence intensity was observed. Hence, an optimum con-
centration of terbium for this study was taken to be a concen-
tration of 2.25 · 106 M.
3.6. Analytical appraisal
A series of standard solutions of FEX (0–1000 ppb) were ana-
lyzed by the proposed method. The obtained calibration curves
were evaluated using linear regression methods. The lumines-
cence intensity I, versus FEX concentration was found to be
linear over the range 10–800 ppb. The calibration equation
was I= 974.6 C–0.566, with a correlation coefﬁcient R2 of
0.9999. The detection limit (S/N ratio = 3) was 1.00 ppb.
The lower limit of quantitation (S/N = 10) was 4.00 ppb.
The reproducibility of the method was obtained for standard
solutions of FEX of 200 ppb and was found to be less than
2% (n= 7).
In the presence of Zn2+ and Et3N, the luminescence inten-
sity I, versus FEX concentration was also found to be linear
over the range 10–800 ppb. The calibration equation was:
I= 1994 C + 0.108, with a correlation coefﬁcient R2 of
0.999. Lower detection and quantitation limits of 0.3 ppb
and 1.00 ppb were obtained respectively. The ﬁgures of meritfexofenadine.
LOD (lg mL1) References
0.283 Pankaniya et al. (2013)
0.27 Krakus et al. (2008)
0.69 Breier et al. (2005)
1.0 · 103 Uno et al., 2004
5.0 · 103 Konieczna et al., 2010
0.006 Alothman et al. (2010)
0.14 Eid and Wahba (2012)
– Guo et al. (2010)
0.001 Al-Lawati et al. (2011)
0.0003 –
escence for the determination of fexofenadine in pharmaceutical formulations.
Table 2 Determination of FEX in pharmaceutical samples using the proposed procedure (n= 7).
Formulation Claimed (mg) Amount found ± SD (mg) Recovery%±RSD
Telfadin 180.0 180.2 ± 3.2 100.1 ± 1.8
Fexodine 120.0 122.5 ± 2.2 102.1 ± 1.8
Telfast 120.0 119.0 ± 3.1 99.1 ± 2.6
Table 3 Determination of FEX in pharmaceutical sample by FL method (n= 7).
Formulation Claimed (mg) Amount found ± SD (mg) Recovery%±RSD t-test F-test
Telfadin 180.0 179.3 ± 1.7 99.6 ± 0.9 0.025 3.54
Fexodine 120.0 119.3 ± 2.4 99.4 ± 2.0 0.097 1.19
Telfast 120.0 117.1 ± 1.6 97.6 ± 1.4 0.584 3.75
Conﬁdence limit at p= 0.05 and six degrees of freedom (df) (t= 2.365).
Tabulated F-value for p= 0.05 and df1 = df2 = 6 (4.28).
6 S.M.Z. Al-Kindy et al.of the proposed method compared favorably with most of the
published methods for the determination of FEX (Table 1). In
addition, the method offered an advantage over other lumines-
cence methods, in that its emission is at a longer wavelength
and free from interference from short-life emitting species pre-
sent in these matrices.
3.7. Determination of FEX in pharmaceutical preparations
The proposed method was applied for the determination of the
concentration of FEX in pharmaceutical formulations of dif-
ferent bands as shown in Table 2. The tablets are known to
contain many excipients as ﬁllers or binder. Three samples
were prepared as described above and were analyzed by the
proposed method. It is clear from the results that good recov-
ery with no interference from the excipients was obtained indi-
cating that the method exhibits good selectivity. For
comparison, FEX in the pharmaceutical formulation was
determined using a spectroﬂuorimetric method (Ibrahim
et al., 2011). These determinations were carried out on the
same batch of samples. The results obtained were compared
statistically using Student t-test and the F-test (Table 3).
Both methods produced comparable accuracy and precision,
which indicates that there is no signiﬁcant difference between
the two methods.
4. Conclusion
In this study, a sensitive and selective method was successfully
developed for the assay of FEX in pharmaceutical prepara-
tions. The proposed method was based on sensitized terbium
time resolved luminescence. The enhancement of the terbium
luminescence upon complexation with FEX has enabled the
assay of this drug with high sensitivity and selectivity where
short-lived emissions were efﬁciently eliminated. The proce-
dure was applied for the determination of FEX in various
tablets with excellent recoveries and reproducibility. The pro-
posed method has the advantage of being simpler, more rapid,
and suitable for automation. It is sensitive to the low amount
of fexofenadine. As a result, the proposed method represents
excellent analytical alternative for the determination ofPlease cite this article in press as: Al-Kindy, S.M.Z. et al., Terbium sensitized lumin
Arabian Journal of Chemistry (2015), http://dx.doi.org/10.1016/j.arabjc.2015.01.016fexofenadine in pharmaceutical formulations. Further work
needs to be done to study the terbium-sensitized luminescence
in aqueous system. This will enable monitoring of FEX in bio-
logical ﬂuid.Acknowledgment
The ﬁnancial support from Department of Chemistry Sultan
Qaboos University is greatly appreciated.
Appendix A. Supplementary material
Supplementary data associated with this article can be found,
in the online version, at http://dx.doi.org/10.1016/j.arabjc.
2015.01.016.References
AbdEl-Hay, S.S., Colyer, C.L., Hassan, W.S., Shalaby, A., 2012.
Spectroﬂuorimetric determination of etodolac, moxepril
hydrochloride and fexofenadine hydrochloride using europium
sensitized ﬂuorescence in bulk and pharmaceutical preparations. J.
Fluoresc. 22, 247–252.
Al-Kindy, S.M.Z., Suliman, F.E.O., 2007. Determination of ibuprofen
in pharmaceutical formulations using terbium sensitized lumines-
cence. Luminescence 22, 294–301.
Al-Kindy, S.M.Z., Suliman, F.E.O., Al-Wishahi, A.A., 2004. A
sequential injection method for the determination of piroxicam in
pharmaceutical formulations using europium sensitized ﬂuores-
cence. Talanta 64, 1343–1350.
Al-Kindy, S.M.Z., Suliman, F.E.O., Al-Wishahi, A.A., Al-Lawati,
H.A.J., Aoudia, M., 2007. Determination of piroxicam in
pharmaceutical formulations and urine samples using europium-
sensitized luminescence. J. Lumin. 127, 291–296.
Al-Kindy, S.M.Z., Al-Harrasi, Z., Suliman, F.E.O., Al-Hamadi, A.,
Pillay, A., 2008. Terbium sensitized luminescence for the deter-
mination of ketoprofen in pharmaceutical formulations. J.
Fluoresc. 19, 245–299.
Al-Kindy, S.M.Z., Al-Habsy, S., Suliman, F.E.O., Al-Lawati, H.A.J.,
2012. Determination of meloxicam using europium sensitized
luminescence in the presence of co-luminescence reagents. J.
Fluoresc. 22, 467–474.escence for the determination of fexofenadine in pharmaceutical formulations.
Terbium sensitized luminescence for the determination of fexofenadine 7Al-Lawati, H.J., Al-Dahmani, Z.M., Suliman, F.O., Al- Kindy,
S.M.Z., Al-Lawati, A.M., 2011. Analysis of fexofenadine in
pharmaceutical formulations using tris(1,10-phenanthroline)-
ruthenium(II) peroxydisulphate chemiluminescence system in a
multichip device. Lumin. J. 26, 762–767.
Alothman, Z.A., Bukhari, N., Haider, S., Wabaidur, S.M., Alwarthan,
A.A., 2010. Spectroﬂuorimetric determination of fexofenadine
hydrochloride in pharmaceutical preparation using silver nanopar-
ticles. Arabian J. Chem. 3, 251–255.
Ansari, A.A., Singh, N., Khan, A.F., Singh, S.P., Iftikhar, K., 2007.
Solvent effect on optical properties of hydrated lanthanide tris–
acetylacetone. J Lumin. 127, 446–452.
Ashour, S., Khateeb, M., Mahrouseh, R., 2013. Extractive spec-
trophotometric and conductometric methods for determination of
fexofenadine hydrochloride in pharmaceutical dosage. Pharm.
Anal. Acta S 2, 003. http://dx.doi.org/10.4172/2153-2435.S2-003.
Bi, W., Wei, T., Lu¨, X., Yani Hui, Song., Zhao, J.S., Wong, W-K.,
Jones, R.A., 2009. Hetero-trinuclear near-infrared (NIR) lumines-
cent Zn2Ln complexes from Salen-type Schiff-base ligands. New J.
Chem. 33, 2326–2334.
Breier, A.R., Garcia, S.S., Jablonski, A., Steppe, M., Schapoval,
E.E.S., 2005. Capillary electrophoresis method for fexofenadine
hydrochloride in capsules. J. AOAC Int. 88, 1059–1063.
Dang, F., Li, Y., Liu, W., 2007. The new ﬂuorescence enhancement
system Tb-N-(2-pyridinyl) ketoacetamide-Et3N-Zn and its applica-
tion. Spectrochim. Acta A 66, 676–680.
Eid, M.I., Wahba, M.E.K., 2012. Validated spectroﬂuorimetric
determination of some H1-receptor antagonists drugs in pharma-
ceutical preparations through charge transfer complexation. J.
Fluoresc. 22, 175–191.
Gazy, A.A., Mahgoub, H., El-Yazbi, F.A., El-Sayed, M.A., Youseff,
R.M., 2002. Determination of some histamine H1-receptor antago-
nists in dosage forms. J. Pharm. Biomed. 15, 859–867.
Guo, D., Zou, J., Zhu, Y., Lou, S., Fan, H., Qin, Q., 2010.
Measurement of fexofenadine concentration in micro-sample
human plasma by a rapid and sensitive LC–MS/MS employing
protein precipitation: application to a clinical pharmacokinetic
study. Biomed. Chromatogr. 24, 335–341.
Hofmann, U., Seiler, M., Drescher, S., Fromm, M.F., 2002.
Determination of fexofenadine in human plasma and urine by
liquid chromatography-mass. J. Chromatogr. B 766, 227–233.
Ibrahim, F., El-Din, M.K., Eid, M.I., Wahba, M.E.K., 2011.
Spectroﬂuorimetric determination of some H1-receptor antagonists
drugs in pharmaceutical formulations and biological ﬂuids. IJPSR
2 (8), 2056–2072.
Kawashima, M., Hirodi, S., 2007. Effect of standard medication on
quality of life of patients with atopic dermatitis. J. Dermatol. 34, 9–
16.
Konieczna, L., Plenis, A., Ole˛dzka, I., Kowalski, P., Ba˛czek, T., 2010.
Rapid RP-LC method with ﬂuorescence detection for analysis of
fexofenadine in human plasma. Chromatographia 71, 1081–1086.Please cite this article in press as: Al-Kindy, S.M.Z. et al., Terbium sensitized lumin
Arabian Journal of Chemistry (2015), http://dx.doi.org/10.1016/j.arabjc.2015.01.016Krakus, S., Ku¨c¸u¨kgu¨zel, I., Ku¨c¸u¨kgu¨zel, S.G., 2008. Development and
validation of a rapid RP- HPLC method for the determination of
cetirizine or fexofenadine with pseudoephedrine in binary pharma-
ceutical dosage forms. J. Pharm. Biomed. 46, 295–302.
Lu¨, X-Q., Feng, W-X., Hui, Y-N., Wei, T., Song, J-R., Zhao, S-S.,
Wong, W-Y., Wong, W-K., Jones, R.A., 2010. Near-infrared
luminescent, neutral, cyclic Zn2 Ln2 (Ln = Nd, Yb, and Er)
complexes from asymmetric Salen-type Schiff base ligands. Eur. J.
Inorg. Chem., 2714–2722
Meeves, S.G., Appajosyula, S., 2003. Efﬁcacy and safety proﬁle of
fexofenadine HCl A unique therapeutic option in H1-receptor
antagonist treatment. J. Allergy Clin. Immunol. 112, S69–S77.
Mikus, P., Vala´skova´, I., Havra´nek, E., 2005. Determination of
fexofenadine in tablets by capillary electrophoresis in free solution
and in solution with cyclodextrins as analyte carriers. Drug Dev.
Ind. Pharm. 31, 795–801.
Naravana, B., Veena, K., 2010. A new method for the spec-
trophotometric determination of fexofenadine hydrochloride.
Indian J. Technol. 17, 386–390.
Pankaniya, M., Patel, P., Shah, J.S., 2013. Stability-indicating HPLC
method for simultaneous determination of Montelukast and
fexofenadine hydrochloride. Indian J. Pharm. Sci. 75 (3), 284–
290.
Qin, W., Zhang, Y., Liu, W., Tan, M., 2003. Synthesis and infrared
and ﬂuorescence spectral properties of luminescent terbium and
europium complexes with open – chain–chain carboxylate crown
ethers. Spectrochim. Acta A 59, 3085–3092.
Simpson, K., Jarvis, B., 2000. Fexofenadine: a review of its use in the
management of seasonal allergic rhinitis and chronic idiopathic
urticaria. Drugs 59, 301–321.
Towatari, T., Nishi, K., Fujinami, T., Matsumoto, N., Sunatsuki, Y.,
Kojima, M., Mochida, N., Ishida, T., Re, N., Mrozinski, J., 2013.
Syntheses, structures, and magnetic properties of acetato- and
diphenolato-bridged 3d–4f binuclear complexes [M(3-
MeOsaltn)(MeOH)x(ac)Ln(hfac)2] (M= ZnII, CuII, NiII, CoII;
Ln = LaIII, GdIII, TbIII, DyIII; 3-MeOsaltn = N, N0-Bis(3-
methoxy-2-oxybenzylidene)-1,3-propanediaminato; ac = Acetato;
hfac = hexaﬂuoroacetylacetonato; x = 0 or 1). Inorg. Chem. 52,
6160–6178.
Uno, T., Yasui-Furukori, N., Takahata, T., Sugawara, K., Tateishi,
T., 2004. Liquid chromatographic determination of fexofenadine in
human plasma with ﬂuorescence detection. J. Pharm. Biomed. 35,
937–942.
Yang, J., Ge, H., Jie, N., Ren, X., Wang, N., Zou, H., 1994.
Study on the co- luminescence system Sm-Gd–BPMPHD–CTMAB
and its analytical application. Fres. J. Anal. Chem. 349, 728–
733.
Yang, X., A Jones, R.A., Lynch, V., Oye, M.M., Holmes, A.L., 2005.
Synthesis and near infrared luminescence of a tetrametallic Zn2Yb2
architecture from a trinuclear Zn3L2 Schiff base complex. Dalton
Trans., 849–851escence for the determination of fexofenadine in pharmaceutical formulations.
